Drug metabolism in drug discovery and development

Acta Pharmaceutica Sinica B

Volumn 8, Issue 5, 2018, Pages 721-732

  Zhang, Zhoupeng ^a   Tang, Wei ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Shanghai ChemPartners ^*  (China)

Author keywords

Bioactivation; Drug discovery and development; Drug metabolism; Metabolite; Pharmacodynamics; Pharmacokinetics; Safety; Toxicity

Indexed keywords

DEUTERIUM; DRUG METABOLITE; PRODRUG;

DRUG DEVELOPMENT; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW; RISK;

EID: 85047228627     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2018.04.003     Document Type: Review

References (50)

1. DiMasi, J.A., Grabowski, H.G., Hansen, R.W., Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47 (2016), 20–33.
2. Zhang, Z., Zhu, M., Tang, W., Metabolite identification and profiling in drug design: current practice and future directions. Curr Pharm Des 15 (2009), 2220–2235.
3. Zhang, D., Luo, D., Ding, D., Lu, C., Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B 2 (2012), 549–561.
4. Trunzer, M., Faller, B., Zimmerlin, A., Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC–MS/MS validation. J Med Chem 52 (2009), 329–335.
5. cam and its L244A mutant. J Am Chem Soc 24 (1997), 5489–5498.
6. cam. Bioorg Med Chem 6 (1998), 1501–1508.
7. Silverman, R.B., Holladay, M.W., Lead discovery and lead modification. Silverman, R.B., Holladay, M.W., (eds.) The Organic Chemistry of Drug Design and Drug Action, 3rd ed., 2014, Academic Press, San Diego, CA, 19–122.
8. Bouska, J.J., Bell, R.L., Goodfellow, C.L., Stewart, A.O., Brooks, C.D., Carter, G.W., Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay. Drug Metab Dispos 25 (1997), 1032–1038.
9. Braeckman, R.A., Granneman, G.R., Rubin, P.R., Kesterson, J.W., Pharmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after single oral administration in man. J Clin Pharmacol, 29, 1989, A22.
10. Reid, J.J., ABT-761 (Abbott). Curr Opin Investig Drugs 2 (2001), 68–71.
11. Li, C.M., Lu, Y., Narayanan, R., Miller, D.D., Dalton, J.T., Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles. Drug Metab Dispos 38 (2010), 2032–2039.
12. Dierks, E.A., Zhang, Z., Johnson, E., De Montellano, P.R., The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant. J Biol Chem 273 (1998), 23055–23061.
13. White, R.E., McCarthy, M.B., Active site mechanics of liver microsomal cytochrome P-450. Arch Biochem Biophys 246 (1986), 19–32.
14. Duquette, P.H., Erickson, R.R., Holtzman, J.L., Role of substrate lipophilicity on the N-demethylation and type I binding of 3-O-alkylmorphine analogs. J Med Chem 26 (1983), 1343–1348.
15. Gotoh, O., Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267 (1992), 83–90.
16. Cupp-Vickery, J.R., Poulos, T.L., Structure of cytochrome P450eryF involved in erythromycin biosynthesis. Nat Struct Biol 2 (1995), 144–153.
17. Lewis, D.F., Dickins, M., Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Metab Rev 35 (2003), 1–18.
18. Lewis, D.F., Jacobs, M.N., Dickins, M., Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 9 (2004), 530–537.
19. Harada, N., Miwa, G.T., Walsh, J.S., Lu, A.Y., Kinetic isotope effects on cytochrome P-450-catalyzed oxidation reactions. Evidence for the irreversible formation of an activated oxygen intermediate of cytochrome P-448. J Biol Chem 259 (1984), 3005–3010.
20. 3 selective and CNS penetrant negative allosteric modulator (NAM). J Med Chem 56 (2013), 3713–3718.
21. Huntington Study Group, Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66 (2006), 366–372.
22. FDA Clinical Pharmacology and Biopharmaceutics Review(s) [Cited 2018 Mar 1]. Available from: 〈https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000ClinPharmR.pdf〉.
23. Auspex Pharmaceuticals, Inc., Auspex Announces Positive Topline Results from Registration Trial of SD-809 for Chorea Associated with Huntington's Disease. [Cited 2018 Mar 1]. Available from: 〈https://globenewswire.com/news-release/2014/12/16/691862/10112630/en/Auspex-Announces-Positive-Topline-Results-From-Registration-Trial-of-SD-809-for-Chorea-Associated-With-Huntington-s-Disease.html〉.
24. Gallant, J.E., Deresinski, S., Tenofovir disoproxil fumarate. Clin Infect Dis 37 (2003), 944–950.
25. Chapman, T.M., McGavin, J.K., Noble, S., Tenofovir disoproxil fumarate. Drugs 63 (2003), 1597–1608.
26. Van Gelder, J., Deferme, S., Naesens, L., et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 30 (2002), 924–930.
27. Lo, M.W., Goldberg, M.R., McCrea, J.B., Lu, H., Furtek, C.I., Bjornsson, T.D., Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58 (1995), 641–649.
28. 1 receptors. Biochem Pharmacol 65 (2003), 1329–1338.
29. Venkatakrishnan, K., Greenblatt, D.J., Von Moltke, Ll, Schmider, J., Harmatz, J.S., Shader, R.I., Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 38 (1998), 112–121.
30. Ulrich, S., Läuter, J., Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet 41 (2002), 853–876.
31. FDA Safety Testing of Drug Metabolites Guidance for Industry [Cited 2017 Jul 12]. Available from: 〈https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm079266.pdf〉.
32. Liu, L., Halladay, J.S., Shin, Y., et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab Dispos 39 (2011), 1840–1849.
33. Smith, G.F., Designing drugs to avoid toxicity. Prog Med Chem 50 (2011), 1–47.
34. Meyer, U.A., Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 24 (1996), 449–459.
35. Racoosin, J.A., Roberson, D.W., Pacanowski, M.A., Nielsen, D.R., New evidence about an old drug—risk with codeine after adenotonsillectomy. N Engl J Med 368 (2013), 2155–2157.
36. Nicholson, W.T., Formea, C.M., Clinical perspective on the clinical pharmacogenetics implementation consortium updated 2014 guidelines for CYP2D6 and codeine. Clin Chem 61 (2015), 319–321.
37. Otton, S.V., Crewe, H.K., Lennard, M.S., Tucker, G.T., Woods, H.F., Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247 (1988), 242–247.
38. Tatsumi, R., Fujio, M., Satoh, H., et al. Discovery of the α7 nicotinic acetylcholine receptor agonists. (R)-3′-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5′-[1′,3′]oxazolidin-2′-one as a novel, potent, selective, and orally bioavailable ligand. J Med Chem 48 (2005), 2678–2686.
39. Evans, D.C., Watt, A.P., Nicoll-Griffith, D.A., Baillie, T.A., Drug–protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17 (2004), 3–16.
40. LoPachin, R.M., DeCaprio, A.P., Protein adduct formation as a molecular mechanism in neurotoxicity. Toxicol Sci 86 (2005), 214–225.
41. Yagen, B., Foureman, G.L., Ben-Zvi, Z., et al. The metabolism and excretion of 14C-styrene oxide-glutathione adducts administered to the winter flounder, Pseudopleuronectes americanus, a marine teleost. Identification of the corresponding S-cysteine derivatives as major urinary metabolites. Drug Metab Dispos 12 (1984), 389–395.
42. 32P-postlabelling in DNA and human embryonal lung fibroblasts (HEL). Carcinogenesis 17 (1996), 801–808.
43. Zhang, Z., Gan, J., Protocols for assessment of in vitro and in vivo bioactivation potential of drug candidates. Zhang, D., Zhu, M., Humphreys, W.G., (eds.) Drug Metabolism in Drug Design and Development: Basic Concepts And Practice, 2008, John Wiley & Sons, New Jersey, 447–476.
44. Tang, W., Zhang, Z., Bioactivation and reactive metabolite assays. Lyubimov, A.V., (eds.) Encyclopedia of Drug Metabolism and Interactions, 2012, John Wiley & Sons, New Jersey, 627–656.
45. 14C]cyanide. Drug Metab Pharmacokinet 24 (2009), 245–254.
46. Meneses-Lorente, G., Sakatis, M.Z., Schulz-Utermoehl, T., De Nardi, C., Watt, A.P., A quantitative high-throughput trapping assay as a measurement of potential for bioactivation. Anal Biochem 351 (2006), 266–272.
47. Gan, J., Harper, T.W., Hsueh, M.M., Qu, Q., Humphreys, W.G., Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem Res Toxicol 18 (2005), 896–903.
48. Zhang, Z., Chen, Q., Li, Y., et al. In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinone type metabolites. Chem Res Toxicol 18 (2005), 675–685.
49. Li, Y., Doss, G.A., Li, Y., Chen, Q., Tang, W., Zhang, Z., In vitro bioactivation of a selective estrogen receptor modulator (2S,3R)-(+)-3-(3-hydroxyphenyl)-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol (I) in liver microsomes: formation of adenine adducts. Chem Res Toxicol 25 (2012), 2368–2377.
50. Singh, J., Petter, R.C., Baillie, T.A., Whitty, A., The resurgence of covalent drugs. Nat Rev Drug Discov 10 (2011), 307–317.